中国のエンテカビル市場2010-2019

China Research and Intelligenceが発行した調査報告書(CRI5062904)
◆英語タイトル:Investigation Report on China Entecavir Market, 2010-2019
◆商品コード:CRI5062904
◆発行会社(リサーチ会社):China Research and Intelligence
◆発行日:2015年6月18日
◆ページ数:30
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:中国
◆産業分野:薬剤・医薬品・材料
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Enterprisewide(全社内共有可)USD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はChina Research and Intelligence社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。China Research and Intelligence社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Description

The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China, among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese is estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.
Entecavir, an oral drug of oral deoxyguanosine, was developed by Bristol-Myers Squibb and approved to enter the market by FDA in Mar. 2005. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd got CFDA’s approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth to some extent. According to CRI’s market survey, the annual sales value of entecavir in China rose from CNY 30 million in 2006 to CNY 1.207 billion in 2014 and CAGR during this period reached up to 55%. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd dominates the Chinese market with a share of over 60% in 2014 for sales value and over 50% for sales volume.
Compared with the original nucleoside analogue, entecavir has stronger antiviral effects, faster onset, fewer side effects and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance. Entecavir makes it possible for patients to start with monotherapy which could be successful over a long term. As is known to all, new drug’s entering into the anti-HBV drug market is bound to pose a threat to old ones, forming a new competitive landscape. Due to the lack of new antiviral drugs for Hepatitis B in a long time, the market demand is far from being satisfied. Therefore, entecavir is estimated to enjoy good market prospects and its sales value will keep growing in the next few years.

Readers can get at least the following information from this report:
-market size of entecavir in China
-competitive landscape of entecavir in Chinese market
-price of entecavir made by different manufacturers in China
-market outlook of entecavir in China

The author suggests the following groups of people purchase this report:
-manufacturers of anti-HBV drugs
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese medicine market, please contact CRI for customized survey service

【レポートの目次】

Table of Contents

1 Related Concepts of Entecavir
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Entecavir in China
2.1 Patent and Approval Status of Entecavir in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Entecavir in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Entecavir in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Entecavir in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Entecavir in China in 2014
6.1 Sino-American Shanghai Squibb Pharmaceuticals Ltd (Trade Name: Baraclude)
6.2 Sichuan Haisco Pharmaceutical Co., Ltd (Trade Name: Gan Bei Qing)
6.3 Shandong Lukang Pharmaceutical Co., Ltd (Trade Name: Mu Chang)
6.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Run Zhong)
6.5 Jiangxi Qingfeng Pharmacy Co., Ltd (Trade Name: Wei Li Qing)
6.6 Fujian Cosunter Pharmaceutical Co., Ltd (Trade Name: En Gan Ding)
6.7 Dawnrays Pharmaceutical Limited (Trade Name: Leiyide)

7Major Manufacturers of Entecavir in Chinese Market, 2010-2014
7.1 Sino-American Shanghai Squibb Pharmaceuticals Ltd
7.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd
7.3 Jiangxi Qingfeng Pharmacy Co., Ltd
7.4 Fujian Cosunter Pharmaceutical Co., Ltd
7.5 Dawnrays Pharmaceutical Limited

8 Market Outlook of Entecavir in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

Selected Charts
Chart Patent Status of Entecavir in China
Chart Approval Information of Entecavir in China
Chart Sales Status of Entecavir in China, 2010-2014
Chart Sales Value of Entecavir in China, 2010-2014
Chart Sales Value of Entecavir in Some Regions in China, 2010-2014
Chart Sales Volume of Entecavir in China, 2010-2014
Chart Market Share of TOP5 Manufacturers of Entecavir for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Entecavir Made by Shanghai Squibb in China, 2010-2014
Chart Sales Value and Market Share of Entecavir Made by Chia Tai Tianqing in China, 2010-2014
Chart Sales Value and Market Share of Entecavir Made by Dawnrays in China, 2010-2014
Chart Sales Value and Market Share of Entecavir Made by Jiangxi Qingfeng in China, 2010-2014
Chart Sales Value and Market Share of Entecavir Made by Fujian Cosunter in China, 2010-2014
Chart Sales Value and Market Share of Entecavir Made by Other Manufacturers in China, 2010-2014
Chart Sales Value and Market Share of Entecavir Capsules in China, 2010-2014
Chart Sales Value and Market Share of Entecavir Tablets in China, 2010-2014
Chart Price of Entecavir Made by Sino-American Shanghai Squibb Pharmaceuticals Ltd in Some Chinese Cities in 2014
Chart Price of Entecavir Made by Sichuan Haisco Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Entecavir Made by Shandong Lukang Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Entecavir Made by Chia Tai Tianqing Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
Chart Price of Entecavir Made by Jiangxi Qingfeng Pharmacy Co., Ltd in Some Chinese Cities in 2014
Chart Price of Entecavir Made by Fujian Cosunter Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Entecavir Made by Dawnrays Pharmaceutical Limited in Some Chinese Cities in 2014



【掲載企業】

Sino-American Shanghai Squibb Pharmaceuticals Ltd; Chia Tai Tianqing Pharmaceutical Group Co., Ltd; Jiangxi Qingfeng Pharmacy Co., Ltd; Fujian Cosunter Pharmaceutical Co., Ltd; Dawnrays Pharmaceutical Limited

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 中国のエンテカビル市場2010-2019(Investigation Report on China Entecavir Market, 2010-2019)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆